Synthesis of the cyclic and acyclic acetal derivatives of 1-(3-C-Ethynyl-β-D-ribo-pentofuranosyl)cytosine, a potent antitumor nucleoside. Design of prodrugs to be selectively activated in tumor tissues via the bio-Reduction-Hydrolysis mechanism

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 11, 2003, Pages 2453-2461

  Nomura, Makoto ^a,b   Shuto, Satoshi ^a   Matsuda, Akira ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 C ETHYNYL 2,3 O (3 AMINOBENZYLIDENE) BETA DEXTRO PENTOFURANOSYL]CYTOSINE; 1 [3 C ETHYNYL 2,3 O (3 NITROBENZYLIDENE) BETA DEXTRO RIBOPENTOFURANOSYL]CYTOSINE; 1 [3 C ETHYNYL 2,3 O (4 AMINOBENZYLIDENE) BETA DEXTRO RIBOPENTOFURANOSYL]CYTOSINE; 1 [3 C ETHYNYL 2,3 O (4 NITROBENZYLIDENE) BETA DEXTRO RIBOPENTOFURANOSYL]CYTOSINE; 1 [3 C ETHYNYL 5 O [1 ETHOXY 1 (3 NITROPHENYL)METHYL] BETA DEXTRO RIBOPENTOFURANOSYL]CYTOSINE; 1 [3 C ETHYNYL 5 O [1 ETHOXY 1 (4 AMINOPHENYL)METHYL] BETA DEXTRO RIBOPENTOFURANOSYL]CYTOSINE; 1 [3 C ETHYNYL 5 O [1 ETHOXY 1 (4 NITROPHENYL)METHYL] BETA DEXTRO RIBOPENTOFURANOSYL]CYTOSINE; 1 [3 C ETHYNYL 5 O [1 ISOPROPOXY 1 (4 AMINOPHENYL)METHYL] BETA DEXTRO RIBOPENTOFURANOSYL]CYTOSINE; 1 [3 C ETHYNYL 5 O [1 ISOPROPOXY 1 (4 NITROPHENYL)METHYL] BETA DEXTRO RIBOPENTOFURANOSYL]CYTOSINE; 1 [3 C ETHYNYL 5 O [1 METHOXY 1 (3 NITROPHENYL)METHYL] BETA DEXTRO RIBOPENTOFURANOSYL]CYTOSINE; 1 [3 C ETHYNYL 5 O [1 METHOXY 1 (4 AMINOPHENYL)METHYL] BETA DEXTRO RIBOPENTOFURANOSYL]CYTOSINE; 1 [3 C ETHYNYL 5 O [1 METHOXY 1 (4 NITROPHENYL)METHYL] BETA DEXTRO RIBOPENTOFURANOSYL]CYTOSINE; 3' ETHYNYLCYTIDINE; 4 AMINOBENZYLIDINE; ACETAL DERIVATIVE; ANTINEOPLASTIC AGENT; BENZYLIDENE DERIVATIVE; NUCLEOSIDE; PRODRUG; UNCLASSIFIED DRUG;

ACIDITY; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; HYDROLYSIS; HYPOXIA; MOUSE STRAIN; NONHUMAN; PH; PHYSIOLOGY; RAT; REDUCTION; TISSUE; TUMOR;

EID: 0038300230     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(03)00104-4     Document Type: Article

References (31)

1. (a) Matsuda A., Hattori H., Tanaka M., Sasaki T. Bioorg. Med. Chem. Lett. 6:1996;1887.
2. (b) Hattori H., Tanaka M., Fukushima M., Sasaki T., Matsuda A. J. Med. Chem. 39:1996;5005.
3. (c) Hattori H., Nozawa E., Iino T., Yoshimura Y., Shuto S., Shimamoto Y., Nomura M., Fukushima M., Tanaka M., Sasaki T., Matsuda A. J. Med. Chem. 41:1998;2892.
4. (a) Tabata S., Tanaka M., Matsuda A., Fukushima M., Sasaki T. Oncology Rep. 3:1996;1029.
5. (b) Tabata S., Tanaka M., Endo Y., Obata T., Matsuda A., Sasaki T. Cancer Lett. 116:1997;225.
6. (c) Takatori S., Tsutsumi S., Hidaka M., Kanda H., Matsuda A., Fukushima M., Wataya Y. Nucleosides Nucleotides. 17:1998;1309.
7. (d) Matsuda A., Fukushima M., Wataya Y., Sasaki T. Nucleosides Nucleotides. 18:1999;811.
8. (e) Takatori S., Kanda H., Takenaka K., Wataya Y., Matsuda A., Fukushima M., Shimamoto Y., Tanaka M., Sasaki T. Cancer Chemother. Pharmacol. 44:1999;97.
9. (f) Shimamoto Y., Fujioka A., Kazuno H., Murakami Y., Ohshimo H., Kato T., Matsuda A., Sasaki T., Fukushima M. Jpn. J. Cancer Res. 92:2001;343.
10. (g) Shimamoto Y., Kazuno H., Murakami Y., Azuma A., Koizumi K., Matsuda A., Sasaki T., Fukushima M. Jpn. J. Cancer Res. 93:2002;445.
11. (h) Shimamoto Y., Koizumi K., Okabe H., Kazuno H., Murakami Y., Nakagawa F., Matsuda A., Sasaki T., Fukushima M. Jpn. J. Cancer Res. 93:2002;825.
12. (a) Sutherland R.M. Cancer. 58:1986;1668.
13. (b) Brown J.M. Cancer Res. 59:1999;5863. and references cited herein.
14. (c) Hay M.P., Lee H.H., Wilson W.R., Roberts P.B., Denny W.A. J. Med. Chem. 38:1995;1928.
15. (a) Jenkins T.C., Nalor M.A., O'Neill P., Threadgill M.D., Colls S., Stratford I.J., Adams G.E., Fielden E.M., Suto M.J., Steir M.J. J. Med. Chem. 33:1990;2603.
16. (b) Mulcahy R.T., Gipp J.J., Schmidt J.P., Joswig C., Borch R.F. J. Med. Chem. 37:1994;1610.
17. (c) Tercel M., Wilson W.R., Anderson R.F., Denny W.A. J. Med. Chem. 39:1996;1084.
18. (d) Shyam K., Penketh P.G., Shapiro M., Belcourt M.F., Loomis R.H., Rockwell S., Sartorelli A.C. J. Med. Chem. 42:1999;941.
19. (a) Tomasz M., Lipman R., Chowdary D., Pawlak J., Verdine G.L., Nakanishi K. Science. 235:1987;1204.
20. (b) Hoey B.M., Bulter J., Swallow J. Biochemistry. 27:1988;2608.
21. (c) Paz M.M., Hopkins P.B. J. Am. Chem. Soc. 119:1997;5999.
22. (d) Nayler M.A., Swann E., Everett S.A., Jaffar M., Nolan J., Robertson N., Lockyer S.D., Patel K.B., Dennis M.F., Stratford M.R.L., Wardman P., Adams G.E., Moody C.J., Stratford I.J. J. Med. Chem. 41:1998;2720. and references cited herein.
23. (e) Tomasz M., Das A., Tang K.S., Ford M.G.J., Minnock A., Musser S.M., Waring M.J. J. Am. Chem. Soc. 120:1998;11581.
24. (a) Mahmud N.P., Garrett S.W., Threadgill M.D. Anticancer Drug Des. 13:1998;655.
25. (b) Berry J.M., Watson C.Y., Whish W.J.D., Threadgil M.D. J. Chem. Soc., Perkin Trans. 1. 1997;1147.
26. Park K.K., Oh C.H., Joung W.K. Tetrahedron Lett. 34:1993;7445.
27. (a) Vaupel P.W., Frinak S., Bicher H.I. Cancer Res. 41:1981;2008.
28. (b) Newell K.J., Tannock I.F. Cancer Res. 49:1989;4477.
29. (c) Vaupel P., Okunieff F.P. Cancer Res. 49:1989;6449.
30. (d) Helmlinger G., Yuan F., Dellian M., Jain R.K. Nature Med. 3:1997;177.
31. HPLC analysis of ECyd (1), which is possible to be produced in the bio-reduction system, was unsuccessful, because cofactors used for the bio-reduction could not be separated from 1 on HPLC.